INBS icon

Intelligent Bio Solutions

2.12 USD
-0.08
3.64%
At close Mar 13, 4:00 PM EDT
After hours
2.19
+0.07
3.30%
1 day
-3.64%
5 days
-10.17%
1 month
-10.55%
3 months
43.24%
6 months
6.00%
Year to date
50.35%
1 year
-53.81%
5 years
-99.92%
10 years
-99.92%
 

About: Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

Employees: 48

0
Funds holding %
of 7,372 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 8 [Q3] → 8 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

4.19% less ownership

Funds ownership: 5.94% [Q3] → 1.75% (-4.19%) [Q4]

75% less capital invested

Capital invested by funds: $437K [Q3] → $108K (-$329K) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for INBS.

Financial journalist opinion

Based on 5 articles about INBS published over the past 30 days

Neutral
GlobeNewsWire
2 days ago
Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the iAccess Alpha Virtual Best Ideas Spring Conference 2025 on March 25 and 26, 2025.
Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th
Neutral
GlobeNewsWire
2 weeks ago
Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriter's Option to Purchase Additional Shares of Common Stock
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced underwritten public offering of 1,500,000 shares of common stock at a public offering price of $2.00 per share of common stock, which included the full exercise of the underwriter's option to purchase up to 195,652 additional shares of common stock. Including the option exercise, the aggregate gross proceeds from the offering were approximately $3.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriter's Option to Purchase Additional Shares of Common Stock
Neutral
GlobeNewsWire
3 weeks ago
Intelligent Bio Solutions Inc. Announces Pricing of $2.6 Million Public Offering of Common Stock
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the pricing of its previously announced underwritten public offering of 1,304,348 shares of common stock at a public offering price of $2.00 per share of common stock, for gross proceeds of approximately $2.6 million, before deducting underwriting discounts and commissions and offering expenses.
Intelligent Bio Solutions Inc. Announces Pricing of $2.6 Million Public Offering of Common Stock
Neutral
GlobeNewsWire
3 weeks ago
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”) a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is commencing an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Intelligent Bio Solutions Inc. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock
Neutral
GlobeNewsWire
4 weeks ago
Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements
Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal second quarter and six months ended December 31, 2024, and provided a business update. "Fiscal Q2 was a successful quarter for the business in   a number of   areas.
Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy
Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 2025 Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 2025
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch
Avon Freight Group selects INBS' fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency
Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales
Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the six months ended December 31, 2024 Higher-margin cartridge sales driving profitability and long-term growth Expanding U.S. and international market presence with FDA submission and strategic partnerships NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its preliminary unaudited selected financial results for the fiscal second quarter and six months ended December 31, 2024.  For the fiscal 2025 second quarter and six-month period, the Company anticipates: Unaudited revenue of approximately $0.61 million for the three months ended December 31, 2024.
Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade
Multilingual upgrade will make INBS' Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas, Europe, Asia and the Middle East, supporting its strategic global expansion goals and planned 2025 entry into the US market. Multilingual upgrade will make INBS' Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas, Europe, Asia and the Middle East, supporting its strategic global expansion goals and planned 2025 entry into the US market.
Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade
Neutral
GlobeNewsWire
1 month ago
Intelligent Bio Solutions Adds Quantum TM to 400+ Account Portfolio Utilizing Breakthrough Fingerprint Drug Testing
Quantum Traffic Management transitions from saliva and urine testing to non-invasive, in-house fingerprint sweat-based drug screening
Intelligent Bio Solutions Adds Quantum TM to 400+ Account Portfolio Utilizing Breakthrough Fingerprint Drug Testing
Charts implemented using Lightweight Charts™